TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15505596
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (1200 mg/d)
Study: 15606398
Drug: Mesalazine micropellets
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine micropellets (3 g/day)
Study: 11599659
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 150 IU/kg s.c. three times weekly (t.i.w.)
Study: 20187135
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (M/EM group)
Study: 1871540
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg intravenous injection every 12 hours until the 3rd postoperative day
Study: 9715861
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg PO BID for 12 weeks
Study: 9933701
Drug: UFT 300
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 300 mg/day (P0 group)
Study: 20017916
Drug: High-energy drink
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy drink (Meltdown RTD); 140 ml administered in two 70 ml doses, separated by 30 min.
Study: 15492476
Drug: Continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing of nitrates (n=86)
Study: 12135034
Drug: 51 g
Normalized name: DIMETHYL SULFONE 0.51 g in 0.51 g ORAL TABLET [MSM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 51 g polyethylene glycol (PEG) laxative
Study: 12135034
Drug: 85 g
Normalized name: UREA 17 g in 85 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 85 g polyethylene glycol (PEG) laxative
Study: 29275880
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Rosuvastatin + Cand+HCTZ)
Study: 24389433
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m² and carboplatin (AUC 6 mg/min/ml) without panitumumab
Study: 16551919
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic wound infiltration with 0.25% bupivacaine 20 mL
Study: 9331228
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg oral alprazolam
Study: 11092290
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (HOE 901)
Study: 9314855
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) administration (150 micrograms intra-arterial bolus, with or without a 10 mg GTN patch for 24 hours)
Study: 23608249
Drug: Lowest vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest vitamin D quartile (1-15.9 ng/ml)
Study: 8590530
Drug: Fibrate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrate therapy
Study: 28940451
Drug: Vilaprisan 2
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 2 mg/day
Study: 7162387
Drug: Pangamic acid
Normalized name: pangamic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pangamic acid (6 tablets of 50 mg per day)
Study: 27579992
Drug: Telephone-delivered problem-solving
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered problem-solving treatment (PST)
Study: 25050589
Drug: Submicron diclofenac
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Submicron diclofenac 35 mg tid
Study: 12564664
Drug: Otic drops
Normalized name: Otic Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otic drops (Dex‐Otic)
Study: 28103950
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (no tube)
Study: 24074360
Drug: DHA 250
Normalized name: DHA 250 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA 250 mg/day
Study: 17845540
Drug: IFN 3
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN 3 MU daily plus ribavirin (RBV) 1000 mg/day for 4 weeks, followed by IFN 3 MU TIW plus RBV 1000 mg/day for 44 weeks (induction)
Study: 17845540
Drug: IFN 5
Normalized name: cpm/PE/DM/acetaminophen/guaifn 5 mg-10 mg-325 mg-200 mg (day)/2 mg-5 mg-10 mg-325 mg(night) ORAL TABLET, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN 5 MU B.I.D. plus RBV 1000-1200 mg/day for 2 weeks, followed by pegylated IFN (PEG-IFN) 75-150 mug weekly plus RBV 1000-1200 mg/day for 46 weeks (induction)
Study: 17845540
Drug: PEG-IFN 75-150
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN 75-150 mug weekly plus RBV 1000-1200 mg/day for 48 weeks (non-induction)
Study: 17850734
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus pioglitazone
Study: 3545941
Drug: Bacampicillin 400
Normalized name: bacampicillin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 400 mg twice daily
Study: 3545941
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily dosages of bacampicillin, ampicillin, amoxycillin
Study: 1495197
Drug: Cefdinir 3
Normalized name: cefdinir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir 3 mg/kg administered 30 minutes after meal
Study: 1495197
Drug: Cefdinir mean
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir mean dose of 4.8 mg/kg t.i.d. for 8 days
Study: 25193003
Drug: Treatment (TX)
Normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (TX)
Study: 22932256
Drug: Menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal hormone therapy (MHT)
Study: 9932568
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone gel
Study: 14659852
Drug: Beta-radiation therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-radiation therapy (188Re-MAG3)
Study: 19222614
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist (DA)
Study: 15559871
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg daily
Study: 6143666
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments
Study: 21539525
Drug: High Drug
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Drug Burden Index (DBI ≥1) after adjustment
Study: 8842510
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (transdermal nicotine patches)
Study: 31115592
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg intravenous infusion) + calcium + calcitriol
Study: 18955426
Drug: Structured educational
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured educational programme of daily incremental physical activity at home (walking and skeletal muscle resistance training, with booklets and written instructions)
Study: 31980143
Drug: Adjuvant capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant capecitabine for six months at the usual dose
Study: 16043733
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg twice a day
Study: 19493418
Drug: Group S1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S1 (propofol target plasma concentration of 4.0 microg/ml)
Study: 19493418
Drug: Group S2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S2 (initial target plasma concentration of 2.0 microg/ml raised to 4.0 microg/ml after 3 minutes)
Study: 23506344
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy alone (Control)
Study: 2920535
Drug: 94 mg
Normalized name: ivacaftor 94 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 94 mg of iron per day as ferrous sulphate with multivitamins
Study: 2007318
Drug: Oral furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral furosemide
Study: 15087628
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg ropivacaine
Study: 29149865
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (CRS) + hyperthermic intra‐operative peritoneal chemotherapy (HIPC) with cisplatin
Study: 8528638
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with IL‐2 and LAK cells
Study: 11171650
Drug: Selective attenuation
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective attenuation of GH‐releasing hormone feedforward signal intensity
Study: 28069654
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM)
Study: 11139109
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (2 x 10^6 KIU pre-CPB, 2 x 10^6 KIU in prime, 500,000 KIU/hr during CPB)
Study: 2692407
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (0.5 mg/kg in 1 liter of saline)
Study: 15146342
Drug: low-dose haloperidol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose haloperidol
Study: 8260856
Drug: Hydroxyzine pamoate
Normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine pamoate (10(‐5) M in 2 ml)
Study: 7294038
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate plus amikacin sulfate therapy
Study: 28853202
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 20 mg/kg/d
Study: 17681259
Drug: Biofield treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofield treatments delivered from a short distance for a total of 30 minutes before and after exposure to hydrogen peroxide.
Study: 16244030
Drug: Small-volume fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-volume fluid management (8 mL.kg(‐1).h(‐1))
Study: 30329136
Drug: Individualized monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Individualized monthly coaching by a physical therapist to adhere to 30 minutes of daily physical activity and 45 minutes of weekly exercise over 18 months
Study: 11739447
Drug: CCK-8 infusion
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK-8 infusion
Study: 22619886
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol 0.5 mcg twice weekly
Study: 22619886
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral calcitriol)
Study: 12175402
Drug: 11 mL
Normalized name: camphor 0.11 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 mL of 2% lignocaine gel rectally
Study: 31356704
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy for PTSD
Study: 17576867
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg BID
Study: 1945511
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy for 24 hours postoperatively
Study: 26603251
Drug: Needling treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needling treatment
Study: 19967342
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) + 2 nucleoside reverse transcriptase inhibitors (2NRTI) once daily
Study: 12871555
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C treatment (1 g day‐1 for 5 days)
Study: 6371627
Drug: melphalan and
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: melphalan and 5‐fluorouracil daily for four days, repeated every four weeks with megace daily for eight weeks
Study: 27329612
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml of fructose beverage
Study: 8546555
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine alone
Study: 7594124
Drug: High-Ca group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Ca group (1,400 mg Ca per day)
Study: 11745911
Drug: Linezolid tablets
Normalized name: Linezolid Tablets
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid tablets administered while fasting
Study: 11745911
Drug: Linezolid tablets
Normalized name: Linezolid Tablets
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid tablets administered after a high-fat meal
Study: 9417761
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of triamcinolonhexacetonid alone (group 2)
Study: 31122843
Drug: Ultrasound-guided erector
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided erector spinae plane block (ESPB) administered preoperatively
Study: 14872476
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg etanercept once weekly
Study: 14872476
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg etanercept twice weekly
Study: 6375874
Drug: Domperidone 30
Normalized name: domperidone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 30 mg
Study: 22925113
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab injection (2 mg/0.08 mL)
Study: 7802179
Drug: 25 G
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 G Whitacre needle
Study: 8590781
Drug: Conventional diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diabetes treatment (control group)
Study: 10753434
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injection (0.2 ml of a 4-mg/ml dexamethasone solution, 0.8 mg per injection)
Study: 20171409
Drug: Active patch
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active patch
Study: 23192219
Drug: Mandated to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandated to community-based outpatient treatment
Study: 17157120
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro 50/50
Study: 15329377
Drug: Implant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant treatment (all attachments)
Study: 24456363
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (5 g/day)
Study: 24141646
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg
Study: 7912819
Drug: Fluphenazine (FLU)
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine (FLU) 2 mg for 2 weeks, then 4 mg for 4 weeks
Study: 30805623
Drug: Wheat DDGS
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat DDGS diet (300 g/kg)
Study: 8606262
Drug: Tirofiban (MK-383)
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tirofiban (MK-383) administered in three sequential dose panels: bolus doses of 5, 10, and 10 microg/kg and continuous infusion doses of 0.05, 0.10, and 0.15 microg/kg per min for 16 to 24 hours
Study: 29766413
Drug: Plaque disclosure
Normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plaque disclosure with subsequent oral hygiene (tooth brushing with prior plaque disclosure)
Study: 28092416
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (360 ELISA units/dose) administered in three different schedules: (i) 0,1,2 months; (ii) 0,1,6 months; (iii) 0,1,12 months
Study: 25483291
Drug: Metformin 1000mg
Normalized name: METFORMIN 1000MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1000mg twice daily
Study: 19208305
Drug: Active depressor
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active depressor treatment with lisinopril or labetalol
Study: 31658994
Drug: Ipilimumab with
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab with stereotactic radiation therapy
Study: 22150036
Drug: Norovirus VLP
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norovirus VLP vaccine
Study: 21335930
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment for hip OA
Study: 11721319
Drug: Atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50-100 mg daily (n = 17)
Study: 20629472
Drug: Besifloxacin ophthalmic
Normalized name: besifloxacin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifloxacin ophthalmic suspension 0.6%
Study: 22679720
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment group (CMM or acupuncture combined during rehabilitation)
Study: 26275583
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (40 IU)
Study: 11805451
Drug: Topical heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical heat application in subjects with myofascial pain
Study: 20037560
Drug: Amoxilav and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxilav and xylometazole at the same doses (control group)
Study: 25524791
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of stimulants and behavioral treatment
Study: 19606406
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment
Study: 10846380
Drug: Atropine lollipop
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine lollipop (0.25 mg)
Study: 10930199
Drug: Hydroxyethylstarch (HES)
Normalized name: hydroxyethylstarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylstarch (HES) 10% 500 ml
Study: 2245382
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (3150 cGy in 18 fractions, 2 to 3 weeks before surgery)
Study: 8353101
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy
Study: 2723128
Drug: Amitriptyline 150
Normalized name: amitriptyline 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 150 mg/day for 4 weeks
Study: 28609128
Drug: Dydrogesterone (duphaston®)
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone (duphaston®) at 10 mg
Study: 8690806
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of bovine myelin